학술논문

Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2020, 38 15, 2p. Supplement: S
Subject
Language
English
ISSN
15277755